MacroGenics Bundle
What's the Story Behind MacroGenics?
MacroGenics, a MacroGenics SWOT Analysis, is a biopharmaceutical company making waves in oncology. Founded in 2000, this MacroGenics company has been pioneering antibody-based therapeutics. Their journey reveals a fascinating blend of scientific innovation and strategic evolution in the challenging world of drug development.
From its early research focusing on immune-based products to its current clinical-stage pipeline, understanding the MacroGenics history is crucial for investors and industry watchers alike. This brief overview of MacroGenics will delve into key milestones, financial performance, and the innovative technology driving its future. Discover the story of a company striving to bring innovative treatments to patients.
What is the MacroGenics Founding Story?
The MacroGenics history began in August 2000, marking the incorporation of the company. The vision of the founders was to create innovative antibody-based therapeutics to address significant medical needs. The initial focus was on developing treatments for cancer and inflammatory diseases.
The scientific foundation of MacroGenics company was built by Drs. Jeffrey Ravetch, LeRoy Hood, Ruedi Aebersold, and Alan Aderem. These individuals brought expertise in immunology, proteomics, and genomics, which was critical for the company's early research. The company's approach centered on engineering antibodies to enhance their effectiveness in eliminating cancer cells.
Early financial backing was crucial for MacroGenics. In September 2001, the company closed a Series A financing round, securing $13.5 million. This funding, provided by investors such as InterWest Partners, MPM Capital, and OrbiMed, was essential for establishing the company and supporting its initial research efforts. A key early collaboration was with the Institute for Systems Biology, which helped identify novel targets using proteomics and genomics technologies.
Key Early Developments
The founding of MacroGenics was driven by the need for novel immunotherapeutics. The company's early focus was on developing monoclonal antibodies and other therapeutic products.
- Incorporation in August 2000.
- Series A financing of $13.5 million in September 2001.
- Collaboration with the Institute for Systems Biology.
- Focus on engineering antibodies to enhance cancer cell elimination.
For more information about the people behind the company, you can check out Owners & Shareholders of MacroGenics.
MacroGenics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of MacroGenics?
During its early growth phase, the biopharmaceutical company, MacroGenics, focused on advancing its pipeline of antibody-based therapeutics. The company has continuously evolved its product candidates, leveraging its proprietary DART (Dual-Affinity Re-Targeting) platform and other next-generation antibody technologies. Key developments include the progression of several product candidates into clinical development, primarily for oncology indications.
Financial Performance
Financially, MacroGenics has seen significant capital raises and strategic partnerships. In 2024, the company's total revenue increased to $150.0 million from $58.7 million in 2023, largely driven by an $85 million increase in milestone payments from its partnership with Incyte. As of December 31, 2024, MacroGenics reported cash, cash equivalents, and marketable securities of $201.7 million, with this cash runway projected to extend into the second half of 2026. In the first quarter of 2025, total revenue was $13.2 million, an increase from $9.1 million in Q1 2024, primarily due to collaborative agreements and contract manufacturing revenue. The company's net loss improved to $41.0 million in Q1 2025, compared to a $52.2 million loss in Q1 2024.
Leadership and Strategy
Leadership transitions have also marked the company's trajectory. Scott Koenig, M.D., Ph.D., a co-founder, served as President and CEO for many years. He intends to step down in early 2025, with a search for his successor underway. The company's growth efforts have been shaped by a competitive landscape in the biotechnology industry, particularly in oncology. MacroGenics has strategically entered into collaborations with global pharmaceutical and biotechnology companies to further develop and commercialize its product candidates.
MacroGenics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in MacroGenics history?
Throughout its history, MacroGenics, a biopharmaceutical company, has achieved several significant milestones in the development of antibody-based therapeutics. These achievements underscore its commitment to advancing innovative treatments for various diseases.
| Year | Milestone |
|---|---|
| December 2020 | FDA approval of MARGENZA® (margetuximab-cmkb) in combination with chemotherapy for adult patients with metastatic HER2-positive breast cancer. |
| November 2022 | U.S. FDA approval of TZIELD® (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes. |
| November 2024 | Sold the global rights to MARGENZA to TerSera Therapeutics for $40 million upfront, with potential for an additional $35 million in sales milestone payments. |
| February 2025 | Incyte filed a supplemental Biologics License Application (sBLA) for retifanlimab, with approval anticipated in the second half of 2025. |
MacroGenics has consistently focused on innovation, particularly in the development of novel antibody-based therapies. A key innovation is their proprietary DART (Dual-Affinity Re-Targeting) platform, which enables the creation of bispecific antibodies.
DART Platform
The DART platform allows for the creation of bispecific antibodies that can simultaneously bind to two different targets.
MARGENZA Approval
The FDA approval of MARGENZA in 2020, in combination with chemotherapy, for HER2-positive breast cancer patients marked a significant achievement.
Partnership with Incyte
The collaboration with Incyte for ZYNYZ® (retifanlimab-dlwr) highlights MacroGenics' ability to partner effectively for drug development.
Partnership with Sanofi
The partnership with Sanofi S.A. for TZIELD® (teplizumab-mzwv) shows MacroGenics' commitment to advancing treatments for type 1 diabetes.
ADC Pipeline
MacroGenics is investing in its emerging antibody-drug conjugate (ADC) pipeline, including MGC026, MGC028, and MGC030.
Strategic Restructuring
The company has been restructuring and re-evaluating its pipeline to focus on promising candidates and emerging technologies.
Despite its successes, MacroGenics has faced challenges inherent in drug development. In early 2025, the company decided to discontinue further internal clinical development of vobra duo.
Clinical Trial Setbacks
The decision to discontinue vobra duo reflects the risks associated with clinical-stage biopharmaceutical development.
Market Downturns and Competition
MacroGenics has navigated market downturns and competitive threats by restructuring and re-evaluating its pipeline.
Financial Adjustments
The sale of MARGENZA rights to TerSera Therapeutics for $40 million upfront, with potential for an additional $35 million in sales milestone payments, reflects strategic financial decisions.
Pipeline Focus
The company is emphasizing its focus on promising candidates like lorigerlimab and its emerging antibody-drug conjugate (ADC) pipeline.
Partnership Strategy
MacroGenics continues to leverage partnerships, such as the one with Incyte, to advance its drug pipeline.
Strategic Shifts
The company's history demonstrates its ability to adapt to challenges through strategic shifts and pipeline adjustments.
To learn more about the financial aspects of the company, consider reading Revenue Streams & Business Model of MacroGenics.
MacroGenics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for MacroGenics?
The MacroGenics history is marked by significant advancements in the biopharmaceutical industry. The company's journey includes key milestones in drug development and strategic collaborations, shaping its position as a leader in antibody-based therapeutics.
| Year | Key Event |
|---|---|
| August 2000 | MacroGenics, Inc. was incorporated. |
| September 2001 | Closed $13.5 million Series A financing. |
| October 2013 | MacroGenics went public with an IPO. |
| 2017 | Licensed ZYNYZ® (retifanlimab-dlwr) to Incyte Corporation. |
| 2018 | Sold TZIELD® (teplizumab-mzwv) to a partner, later acquired by Sanofi. |
| December 2020 | MARGENZA® (margetuximab-cmkb) received FDA approval. |
| November 2022 | TZIELD® received U.S. FDA approval to delay the onset of Stage 3 type 1 diabetes. |
| July 2024 | Achieved $100.0 million in milestones from Incyte related to retifanlimab. |
| November 2024 | Sold global rights to MARGENZA to TerSera Therapeutics for $40 million upfront, with potential for $35 million in sales milestones. |
| December 2024 | Incyte filed sBLA for retifanlimab. |
| Late 2024 | LORIKEET Phase 2 study of lorigerlimab in mCRPC is fully enrolled. |
| Early 2025 | Discontinued further internal clinical development of vobra duo. |
| February 2025 | Incyte disclosed sBLA filing for retifanlimab. |
| March 20, 2025 | Reported 2024 financial results, showing $150.0 million in total revenue and a net loss of $67.0 million. |
| March 31, 2025 | Cash, cash equivalents and marketable securities stood at $154.1 million. |
| Q1 2025 | Dosed first patient in LINNET Phase 2 study of lorigerlimab for ovarian cancer. |
| April 2025 | Sanofi anticipates TZIELD-related regulatory decisions in the E.U. and China in the second half of 2025. |
| May 2025 | Reported Q1 2025 financial results, with total revenue of $13.2 million and a net loss of $41.0 million. |
| June 10, 2025 | Management to present at the Goldman Sachs 46th Annual Global Healthcare Conference. |
Future Outlook
MacroGenics anticipates its cash, cash equivalents, and marketable securities of $154.1 million as of March 31, 2025, and future payments from partners will extend its cash runway into the second half of 2026. The company is focused on advancing its novel pipeline of clinical product candidates.
Lorigerlimab Development
Clinical updates for the LORIKEET Phase 2 study of lorigerlimab are expected in the second half of 2025. This highlights the company's commitment to progressing its clinical programs and addressing unmet medical needs in cancer treatment.
ADC Pipeline
MacroGenics is also progressing its emerging antibody-drug conjugate (ADC) pipeline. MGC026 (targeting B7-H3) is in Phase 1 dose escalation with expansion planned for 2025, and MGC028 (targeting ADAM9) is also in Phase 1 trials.
Strategic Initiatives
An IND filing for MGC030 is planned for 2026. The company continues to explore potential partnerships for vobra duo. These initiatives reflect the company's commitment to innovation and strategic collaborations.
MacroGenics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of MacroGenics Company?
- What is Growth Strategy and Future Prospects of MacroGenics Company?
- How Does MacroGenics Company Work?
- What is Sales and Marketing Strategy of MacroGenics Company?
- What is Brief History of MacroGenics Company?
- Who Owns MacroGenics Company?
- What is Customer Demographics and Target Market of MacroGenics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.